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CASE LETTERSSuccessful treatment of discoid lupus
erythematosus with fumaric acid esters
To the Editor: Fumaric acid esters (FAEs) have proven
their therapeutic efficacy in moderate to severe
psoriasis and have been licensed in Germany since
1994. The most pharmacologically effective mole-
cule among the FAEs is dimethyl fumarate.1 It has
previously been shown that this lipophilic molecule
inhibits the activity of the transcription factor NF-B
and the secretion of proinflammatory cytokines by
T cells.2 Several further antipsoriatic effects of FAEs
have been suggested, including the induction of
pro-apoptotic pathways, the suppression of adhe-
sion molecules, and the inhibition of keratinocyte
proliferation. The efficacy of FAEs in psoriasis may
therefore bemediated by immunomodulatory mech-
anisms, which might also play a role in the treatment
of other inflammatory diseases, such as cutaneous
lupus erythematosus.
Here we report systemic treatment with FAEs in a
52-year-old woman with discoid lupus erythemato-
sus presenting with severe erythematous, scarring
lesions on the face (Table I; Fig 1, A and B). Previous
therapies included topical glucocorticoids, tacroli-
mus ointment, hydroxychloroquine, chloroquine,
and alitretinoin with only short-term improvement.
The patient was included in a pilot study, and
Fumaderm initial (Biogen Idec, Cambridge, MA)
(30 mg dimethyl fumarate and 75 mg monoethyl
fumarate salts) was administered orally e 1 tablet
up to 3 tablets per day. The Revised Cutaneous Lupus
Disease Area and Severity Index (RCLASI), a vali-
dated disease activity and damage scoring system,
was used to evaluate the patient’s skin lesions during
the treatment period.3 The patient did not receive
any additive therapeutic agent other than Fumaderm
initial. The activity of the discoid lesions decreased
from 17 points to 8 points, and the damage from 5
points to 3 points, which was a clear improvement
after 6 months of treatment (Fig 1, C and D). Severe
adverse events were not recorded during treatment
with FAEs; however, the patient only tolerated the
starting dose of 1 tablet of Fumaderm initial. A higher
dose resulted in nausea, diarrhea, headache, flush,
and abdominal cramps. Consequently, it was not
possible to switch from Fumaderm initial to
Fumaderm (Biogen Idec, Cambridge, MA) (120 mg
dimethyl fumarate and 95 mg monoethyl fumarate
salts). After 6 months of treatment, Fumaderm initial
was discontinued according to the study protocol,J AM ACAD DERMATOL
Open access under CC BY-NC-ND license.and the skin lesions became severely aggravated.
The treatment with Fumaderm initial was started
again and the patient reported significant improve-
ment after some weeks. Moreover, the patient then
had fewer side effects from therapy and even
tolerated 1 tablet of Fumaderm per day.
To our knowledge, to date, only 1 case of discoid
lupus erythematosus treated with FAEs in combina-
tion with hydroxychloroquine has been published.
Furthermore, a poster presentation has described the
effective treatment with FAEs of a patient with lupus
erythematosus tumidus and a patient with systemic
lupus erythematosus (Table I).4,5 In summary, these
case reports suggest that FAEs could be an effective
alternative treatment of cutaneous lupus erythema-
tosus; however, randomized controlled trials are
warranted to evaluate the efficacy and safety of
FAEs in this disease.
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Table I. Demographic and clinical data of patients treated with fumaric acid esters
Reference Sex Age Subtype Clinical manifestations Previous therapy: ineffective
Fumaderm
agent Therapeutic regimen Clinical response Adverse effects
Balak et al,
20114
F 35 LET Erythematous,
indurated swelling
of the nose, present
for 1 year
Hydroxychloroquine, intralesional
steroid injections
Fumaderm
initial
Dosage was gradually
increased up to 6
tablets per day
Lesions resolved
completely within
3 months of
treatment
Nausea, diarrhea,
mild leukopenia
and proteinuria
Balak et al,
20114
F 24 SLE Erythematous, scaly
plaques, Raynaud
phenomenon,
alopecia, and oral
ulcers
Prednisone, hydroxychloroquine,
cyclosporine
Fumaderm
initial
Dosage was gradually
increased up to 6
tablets per day in
combination with
10 mg prednisone
Good effects within
3 months of
treatment
Tiredness, pruritus,
abdominal
cramps, transient
proteinuria
Klein et al,
20125
M 42 DLE Erythematous, scarring
discoid lesions on
both cheeks and
the chin
Hydroxychloroquine, topical
steroids, tacrolimus ointment
Fumaderm
initial,
Fumaderm
Dosage was gradually
increased up to
6 tablets of
Fumaderm per day
in combination with
hydroxychloroquine
Complete resolution
of erythematous
lesions (stable
disease), 73
months of
treatment
Not available
Present case
report
F 52 DLE Severe, erythematous,
scarring discoid
lesions on the face
Hydroxychloroquine, chloroquine,
alitretinoin, topical steroids,
tacrolimus ointment
Fumaderm
initial
(Fumaderm
was not
tolerated
during the
study)
Dosage was gradually
increased up to 3
tablets per day
RCLASI activity of
discoid lesions
decreased from 17
to 8 points and
RCLASI damage
from 5 to 3 points
after 6 months of
treatment
Nausea, diarrhea,
headache, flush,
abdominal
cramps
DLE, Discoid lupus erythematosus; LET, lupus erythematosus tumidus; RCLASI, Revised Cutaneous Lupus Disease Area and Severity Index; SLE, systemic lupus erythematosus.
J
A
M
A
C
A
D
D
E
R
M
A
T
O
L
JU
LY
20
14
e
1
6
Letters
Fig 1. Cutaneous lupus erythematosus. Erythematous, scarring discoid lesions on the face
before (A and B) and after 6 months of treatment with Fumaderm initial (C and D). Courtesy of
the Photographic Laboratory (with thanks to J. Bueckmann and P. Wissel), Department of
Dermatology, University of Muenster, Germany.
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http://dx.doi.org/10.1016/j.jaad.2013.12.004Fig 1. Miliarial gout. Erythematous pink to yellow papules
over the extensor forearms with a firm 2-cm nodule on the
right elbow.Miliarial gout: A rare clinical presentation
To the Editor: Chronic cutaneous tophaceous gout is
a manifestation of untreated gouty arthritis that
manifests as monosodium urate crystal deposition
intradermally or within the subcutaneous tissues of
the skin usually over joints or on the ears. Multiple
clinical variants of tophaceous gout have been
described.1 Miliarial gout is an extremely rare
manifestation of tophaceous gout and refers to
‘‘milia-like’’ widely distributed papules containing
white to cream colored material on an erythematous
base.1,2 Here we describe a case of miliarial gout in apatient with a normal serum uric acid level and no
previous medical history of gouty arthritis.
A 43-year-old Caucasian man presented with
grouped, tender, yellowish-red papules that
occurred in crops over the metacarpophalangeal
joints of his hands, knees, abdomen, extensor
